Genomadix Bioscience receives FDA clearance for first rapid DNA test of mutations affecting metabolism of common drugs.

01/24/2018

Genomadix Bioscience today announced that the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of the Genomadix RX CYP2C19 System. It provides genetic results in less than 60 minutes from a non-invasive cheek swab.